GSK's Pandemrix vaccine, which was a split virus vaccine incorporating an adjuvant, produced a greater immune response than Baxter's Celvapan vaccine.
Pandemrix also had high seroconversion rates in children aged less than three years, but led to more reactions in children, Dr Claire Waddington and colleagues from Oxford University's Department of Paediatrics found.
Writing in the BMJ, the researchers commented: ‘These data provide important information to guide immunisation policy in an influenza pandemic and indicate the potential for improved immunogenicity of seasonal influenza vaccines in children.'
